The presence of pre-existing neutralizing autoAb against IFN-I, first described in SLE and subsequently in patients treated with IFN (alpha or beta) has been demonstrated to account for at least 10–20% of severe COVID19 with pneumonia the anti–IFN–I autoAb are absent from asymptomatic/mild COVID-19 [33]. Here, IFNA1 is linked to COVID-19.